Vitalis Therapeutics Inc. — The consolidated register for the VitaFlow (VTX-401) program: risks, assumptions, issues, decisions and dependencies, plus approved changes and live gate conditions, as at 15 October 2026.
How This Register Works
Five categories in one document. They are kept together because items move between them:
An assumption is something the plan depends on and has chosen not to verify. If it becomes doubtful it is re-classified as a risk, with a probability and a response. If it materialises it becomes an issue, with an owner and a recovery. When it is resolved in a way that binds future work, it becomes a decision. A dependency is the special case where the thing depended on is another piece of work rather than a state of the world.
Splitting these across separate registers — a risk register, an issues log, a decision log — is common and loses exactly the transitions that matter. I-02 below is a live example: it was not on the original risk register at all, which is itself a finding.
Risks
7 open risks, 2 rated High. Both High risks are clinical, which is the correct profile for an asset in Phase 3 — the principal uncertainty in this program is the molecule, not its execution. A Phase 3 program whose top risks were all operational would be telling you either that the molecule is a certainty, which it is not, or that the register is being written by people who do not want to name the real exposure.
| Ref | Risk | Severity | Category | Owner | Horizon | Response |
|---|---|---|---|---|---|---|
| R-01 | Phase 3 efficacy does not separate sufficiently from approved products in the class | High | Clinical | Dr. S. Aldridge | Jun 2028 | Phase 2 dose-ranging carried a wider dose span than required for selection alone; the top dose was retained into Phase 3. |
| R-02 | Gastrointestinal tolerability drives discontinuation above the modelled rate | High | Clinical | Dr. S. Aldridge | Dec 2027 | Extended dose-escalation schedule adopted after Phase 2; discontinuation is a monitored endpoint with DMC review. |
| R-03 | Registration-batch manufacture or process validation slips against the NDA date | Medium | CMC | Dr. K. Oyelaran | Mar 2028 | Dual-source qualification from Gate 4 (D-05); stability protocol started at the earliest supportable point. |
| R-04 | A competitor approval changes the evidentiary bar before filing | Medium | Market | J. Barrington | Sep 2028 | Differentiation rests on tolerability rather than magnitude of effect; the comparator sub-study (D-08) exists for this. |
| R-05 | Phase 3 enrolment runs behind the planned curve | Medium | Clinical | Dr. R. Molyneux | Jun 2027 | Site over-recruitment against plan; obesity clinic partnerships; pre-screening registry. |
| R-06 | Payer coverage at launch is narrower than the business case assumes | Medium | Commercial | J. Barrington | Mar 2029 | Health-economic evidence package built alongside Phase 3, not after it; payer advisory boards from 2027. |
| R-07 | Pre-approval inspection finds a deficiency at the contract manufacturer | Low | Quality | Dr. I. Solberg | Jan 2029 | Two internal audits scheduled ahead of the inspection window; QA embedded at site from registration batches. |
Issues
2 open of 3.
| Ref | Issue | Status | Severity | Owner | Raised | Recovery |
|---|---|---|---|---|---|---|
| I-01 | Phase 1 recruitment ran four weeks behind plan | Closed | Medium | Dr. R. Molyneux | 14 Nov 2023 | Two additional units activated. Recovered inside Stage 2; no gate impact. |
| I-02 | Analytical method transfer to Aldergate did not meet acceptance criteria first pass | Open | High | Dr. K. Oyelaran | 09 Mar 2026 | CMC team embedded on site; re-qualification complete for two of three methods. Contingency drawn. |
| I-03 | Two Phase 3 sites failed activation on IRB timelines | Open | Low | Dr. R. Molyneux | 02 Sep 2026 | Replacement sites identified from the reserve list; no change to the enrolment curve. |
It is recorded here with that history rather than tidied into a risk that was foreseen, because the useful lesson is the miss: technical transfer between organizations is where programs lose time, and treating it as execution rather than risk is a recurring error.
Assumptions
An assumption is a decision not to spend money resolving something. Each one below is a place where the plan has accepted exposure deliberately.
| Ref | Assumption |
|---|---|
| A-01 | FDA accepts the co-primary endpoints agreed at the End-of-Phase-2 meeting (percent change in body weight and proportion achieving ≥5% reduction) without further modification. |
| A-02 | Standard 10-month review applies. Neither priority review nor a breakthrough designation is assumed in the plan or the business case. |
| A-03 | No advisory committee meeting is convened. Budget carries no line for advisory committee preparation. |
| A-04 | Phase 3 enrolment completes within the planned window at the planned site count, on the recruitment rates observed in Phase 2. |
| A-05 | Aldergate Biologics has registration-batch capacity available in the Stage 4 window as contracted. |
| A-06 | Payer coverage for chronic weight management continues to broaden over the launch horizon; the case does not assume Medicare Part D coverage. |
A-02 and A-03 are conservative in the direction that matters: the plan assumes neither expedited review nor an advisory committee. An expedited review would pull revenue forward; an advisory committee would add cost and time the budget does not carry. Where an assumption must be wrong, it is better that it is wrong in the direction that creates slack rather than the one that creates a gap.
A-06 is the weakest assumption in the set and is the one most likely to move. It is paired with R-06 and with GC-03, the at-risk gate condition.
Decisions
9 decisions binding on the program. Each was taken at or before a gate and recorded in the minutes; the rationale is preserved so that a later reader can see what was known at the time rather than reconstruct it.
| Ref | Decision | Rationale |
|---|---|---|
| D-01 | File a 505(b)(1) NDA as a new molecular entity rather than a 505(b)(2) | No suitable listed drug to reference; the molecule is novel. 505(b)(2) was assessed and closed at Gate 1. |
| D-02 | Once-weekly subcutaneous prefilled pen; no oral formulation at launch | Oral bioavailability work would add an estimated 18 months and a second CMC program for a segment the launch case does not require. |
| D-03 | United States first; EU marketing authorization deferred to Year 4+ | Concentrates regulatory and commercial effort on one pathway; avoids parallel EMA scientific advice and a second CMC dossier during Phase 3. |
| D-04 | Outsource Phase 2 and Phase 3 execution to a single full-service CRO | Building internal trial operations for a single asset does not pay back. Single-vendor rather than functional service provider model, for accountability at the trial level. |
| D-05 | Single-source drug substance through Phase 2; dual-source from Gate 4 | Qualifying a second source before Phase 2 read-out risks spend on an asset that may not proceed. |
| D-06 | Carry a dedicated cardiovascular outcomes sub-study inside Phase 3 (CR-02) | Aligns with agency expectations for chronic metabolic therapy and pre-empts a post-marketing requirement. |
| D-07 | Carry class labeling for thyroid C-cell tumors; propose no REMS at filing | Consistent with approved products in the class. A REMS proposal is not supported by the safety database and would be a commercial disadvantage if volunteered. |
| D-08 | Placebo-controlled pivotal trials with an active-comparator sub-study | Placebo control is required for the registration endpoint; the comparator arm serves market access, not approval. |
| D-09 | Chair of the Development Committee does not hold a vote | The person accountable for program progress is not the person who decides whether it continues. |
Dependencies
| Ref | Dependency |
|---|---|
| DEP-01 | IND acceptance (30-day safety review) before any first-in-human dosing. |
| DEP-02 | Phase 2 dose selection before Phase 3 protocol finalisation. |
| DEP-03 | Registration batches manufactured and on stability before NDA submission. |
| DEP-04 | Process validation complete before the pre-approval inspection. |
| DEP-05 | Database lock before topline analysis; topline before NDA assembly begins. |
Every entry is a hard sequence rather than a preference. DEP-03 and DEP-04 are the pair that most often move a filing date, because manufacturing readiness is routinely planned as though it runs parallel to clinical read-out when in practice the registration batches gate the submission independently of whether the data are ready.
Approved Changes
| Ref | Change | Status | Approved | Effect |
|---|---|---|---|---|
| CR-01 | Add an Asian-population cohort to Phase 2 | Approved | 09 Oct 2024 | Increases N by 50. Supports the later EU and Asia-Pacific strategy without a separate bridging study. |
| CR-02 | Add a cardiovascular outcomes sub-study to Phase 3 | Approved | 20 Apr 2026 | Adds $6,400,000 and six months to the Phase 3 window. Pre-empts a post-marketing requirement (D-06). |
CR-02 is carried as a change with a contingency draw of $7,200,000, not as a Phase 3 overrun. The distinction matters to anyone reading variance later: the scope was added deliberately, on agency expectation, and recording it as an overrun would misattribute a governance decision to poor estimation.
Gate Conditions
Conditions attached to the Gate 4 GO WITH CONDITIONS (5-0-1) outcome.
| Ref | Condition | Owner | Due | Closed | Status | Addresses |
|---|---|---|---|---|---|---|
| GC-01 | Complete analytical method re-qualification at Aldergate for all three methods | Dr. K. Oyelaran | 18 Dec 2026 | — | open | I-02; the CMC readiness score recorded at Gate 4 |
| GC-02 | Confirm the cardiovascular sub-study protocol with the DMC before first CV-cohort dosing | Dr. S. Aldridge | 30 Nov 2026 | 25 Sep 2026 | closed | CR-02 scope addition |
| GC-03 | Stand up the payer evidence plan and hold the first advisory boards | J. Barrington | 31 Mar 2027 | — | at-risk | R-06; the market access score recorded at Gate 4 |